FindTrial
Sign In

20vPnC

BIOLOGICAL7 trials

Sponsors

Pfizer

Conditions

Pneumococcal Disease

Phase 1

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults
CompletedNCT07019909
PfizerPneumococcal Disease
Start: 2025-07-06End: 2026-01-28Updated: 2026-02-25
A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
Active, not recruitingNCT07023081
PfizerPneumococcal Disease
Start: 2025-06-15End: 2027-05-14Updated: 2026-03-12

Phase 3

Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
CompletedNCT03760146
PfizerPneumococcal Disease
Start: 2018-12-12End: 2019-12-16Updated: 2021-12-02
Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
CompletedNCT03828617
PfizerPneumococcal Disease
Start: 2019-02-14End: 2019-10-09Updated: 2020-11-23
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination
CompletedNCT03835975
PfizerPneumococcal Disease
Start: 2019-02-12End: 2020-02-12Updated: 2021-02-21
Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
CompletedNCT04642079
PfizerPneumococcal Disease
Start: 2020-12-04End: 2022-04-06Updated: 2024-01-22
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
CompletedNCT04875533
PfizerPneumococcal Disease
Start: 2021-06-14End: 2022-05-13Updated: 2024-11-05

Related Papers

A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan
Vaccine2024-01-2315 citations
Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
Human Vaccines & Immunotherapeutics2022-11-117 citations
Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years
Clinical Infectious Diseases2021-12-22152 citations
A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
2021-11-2549 citations
Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20.
2021-10-2713 citations
A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.
2021-07-2451 citations
A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age
Human Vaccines & Immunotherapeutics2021-03-042 citations
A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States
Human Vaccines & Immunotherapeutics2021-02-0515 citations
Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
Clinical Infectious Diseases2020-07-22156 citations